Lördag 22 Februari | 05:32:09 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2025-10-22 07:50 Kvartalsrapport 2025-Q3
2025-07-18 07:50 Kvartalsrapport 2025-Q2
2025-04-30 N/A X-dag ordinarie utdelning VIMIAN 0.00 SEK
2025-04-29 N/A Årsstämma
2025-04-29 07:50 Kvartalsrapport 2025-Q1
2025-02-13 - Bokslutskommuniké 2024
2024-10-24 - Kvartalsrapport 2024-Q3
2024-08-15 - Kvartalsrapport 2024-Q2
2024-05-23 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2024-05-22 - Årsstämma
2024-05-02 - Kvartalsrapport 2024-Q1
2024-02-15 - Bokslutskommuniké 2023
2023-11-08 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-06-02 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2023-06-02 - Årsstämma
2023-05-04 - Kvartalsrapport 2023-Q1
2023-03-24 - Extra Bolagsstämma 2023
2023-03-08 - Bokslutskommuniké 2022
2022-11-16 - Kvartalsrapport 2022-Q3
2022-10-03 - Extra Bolagsstämma 2022
2022-08-24 - Kvartalsrapport 2022-Q2
2022-06-03 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2022-06-02 - Årsstämma
2022-05-24 - Kvartalsrapport 2022-Q1
2022-03-09 - Bokslutskommuniké 2021
2021-11-26 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Vimian Group är en koncern verksamma inom djurhälsa. Bolaget levererar via sina dotterbolag läkemedel och tekniska lösningar till veterinärer, laboratorier och husdjursägare. Produkterna inkluderar exempelvis läkemedel med tillhörande klinisk forskning samt digitala plattformar för veterinärkliniker. Bolaget är verksamma på en global nivå med huvudkontor i Stockholm.
2025-02-13 07:45:00

Record sales quarter closes an eventful year

  • Net revenue for the quarter increased by 27 per cent to EUR 104.9m (82.5) with organic growth of 15 per cent
  • Adjusted EBITA increased 9 per cent to EUR 24.6m (22.6), corresponding to a margin of 23.4 per cent (27.5)
  • Operating profit (EBIT) of EUR 12.5m (2.7)
  • Profit of EUR 12.5m (-6.3) and earnings per share before and after dilution EUR 0.02 (-0.01)
  • Cash flow from operating activities of EUR 24.4m (17.2)

“Vimian closed an eventful year with all-time high revenues in the fourth quarter, reaching EUR 104.9 million. We continued to report strong organic growth of 15 per cent, ahead of the overall animal health market”, says Patrik Eriksson, CEO Vimian Group.

Revenue for the full year increased by 13 per cent to EUR 374.8m (331.7) with organic growth of 9 per cent. Adjusted EBITA increased by 9 per cent to EUR 95.2m (87.3) corresponding to a margin of 25.4 per cent (26.3). Cash flow from operations reached EUR 58.1m (-28.6).

“In 2024, we have delivered strong results and achieved several key milestones including new financial targets, a successful rights issue and our entrance into the fast-growing niche veterinary dental. We are well-positioned to continue drive strong profitable growth by addressing significant white space in our market niches and complete value-creative acquisitions”, concludes Patrik Eriksson.

A telephone and webcast will be held for investors, analysts, and media, today at 09.00 (CET). The conference will be held in English and include a question-and-answer session.

To attend the telephone conference:
Dial-in number to the teleconference will be received by registering on the link below. After the registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference.
https://conference.inderes.com/teleconference/?id=5006112

To attend the webcast:
Link: https://vimian-group.events.inderes.com/q4-report-2024

Related presentation materials will be available on Vimian’s website (https://vimian.com/investors/reports-and-presentations/) ahead of the telephone and web conference.